Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/25726
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMease, Philip J.-
dc.contributor.authorKavanaugh, Arthur-
dc.contributor.authorReimold, Andreas-
dc.contributor.authorTahir, Hasan-
dc.contributor.authorRech, Juergen-
dc.contributor.authorHall, Stephen-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorPascale, Pellet-
dc.contributor.authorDelicha, Evie Marie-
dc.contributor.authorPricop, Luminata-
dc.contributor.authorMpofu, Shepard-
dc.date.accessioned2018-03-08T12:55:38Z-
dc.date.available2018-03-08T12:55:38Z-
dc.date.issued2017-
dc.identifier.citationANNALS OF THE RHEUMATIC DISEASES, 76, p. 952-953 (Art N° SAT0470)-
dc.identifier.issn0003-4967-
dc.identifier.urihttp://hdl.handle.net/1942/25726-
dc.description.sponsorshipP. Mease Grant/research support from: Abbvie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, Consultant for: Abbvie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, A. Kavanaugh Consultant for: Novartis, A. Reimold Grant/research support from: AbbVie, H. Tahir Speakers bureau: Novartis, Eli Lilly, and Abbvie, J. Rech Speakers bureau: Abbvie, BMS, Celgene, Fresenius, medicap, MSD, Novartis, Pfizer, and Roche, S. Hall: None declared, P. Geusens Grant/research support from: Pfizer, Abbott, Lilly, Amgen, MSD, Will, Bio Minerals and Roche, Speakers bureau: Pfizer, Abbott, Lilly, Amgen, MSD, Will, Bio Minerals and Roche, P. Pascale Shareholder of: Novartis, Employee of: Novartis, E. M. Delicha Employee of: Novartis, L. Pricop Shareholder of: Novartis, Employee of: Novartis, S. Mpofu Shareholder of: Novartis, Employee of: Novartis-
dc.language.isoen-
dc.publisherBMJ PUBLISHING GROUP-
dc.subject.othermonoclonal antibodies; Psoriatic arthritis; randomized trials and safety-
dc.titleSecukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 14-17, 2017-
local.bibliographicCitation.conferencenameAnnual European Congress of Rheumatology-
local.bibliographicCitation.conferenceplaceMadrid, SPAIN-
dc.identifier.epage953-
dc.identifier.spage952-
dc.identifier.volume76-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Mease, P. J.] Swedish Med Ctr, Seattle, WA USA. [Mease, P. J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, A.] UC San Diego Sch Med, La Jolla, CA USA. [Reimold, A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, H.] Barts Hlth NHS Trust, London, England. [Rech, J.] Univ Erlangen Nurnberg, Erlangen, Germany. [Hall, S.] Monash Univ, Melbourne, Vic, Australia. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Geusens, P.] Maastricht Univ Hosp, Maastricht, Netherlands. [Pascale, P.; Delicha, E. M.; Mpofu, S.] Novartis Pharma AG, Basel, Switzerland. [Pricop, L.] Novartis Pharmaceut, E Hanover, NJ USA.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrSAT0470-
dc.identifier.doi10.1136/annrheumdis-2017-eular.1260-
dc.identifier.isi000413181402756-
dc.identifier.urlhttp://ard.bmj.com/content/76/Suppl_2/952-
item.contributorMease, Philip J.-
item.contributorKavanaugh, Arthur-
item.contributorReimold, Andreas-
item.contributorTahir, Hasan-
item.contributorRech, Juergen-
item.contributorHall, Stephen-
item.contributorGEUSENS, Piet-
item.contributorPascale, Pellet-
item.contributorDelicha, Evie Marie-
item.contributorPricop, Luminata-
item.contributorMpofu, Shepard-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.fullcitationMease, Philip J.; Kavanaugh, Arthur; Reimold, Andreas; Tahir, Hasan; Rech, Juergen; Hall, Stephen; GEUSENS, Piet; Pascale, Pellet; Delicha, Evie Marie; Pricop, Luminata & Mpofu, Shepard (2017) Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial. In: ANNALS OF THE RHEUMATIC DISEASES, 76, p. 952-953 (Art N° SAT0470).-
crisitem.journal.issn0003-4967-
crisitem.journal.eissn1468-2060-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
10.1136@annrheumdis-2017-eular.1260.pdf
  Restricted Access		Published version562.59 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.